(Total Views: 551)
Posted On: 08/26/2021 5:17:55 PM
Post# of 145247
“Dr. Srinivasan provides 30 years of broad regulatory and drug development experience including a career serving as Director of CMC Regulatory Affairs for Regeneron Pharmaceuticals, Inc. where he led the CMC strategy and successfully submitted a monoclonal antibody based BLA (Dupixent approved in 2017) “
Now we have something to talk about.
Now we have something to talk about.
![](/m/images/thumb-up.png)
![](/m/images/thumb-down.png)